Skip to main content
. 2015 May 8;6(24):20231–20240. doi: 10.18632/oncotarget.4047

Figure 5. Rigosertib suppresses growth and alters signaling in Philadelphia (Ph)-positive primary cells.

Figure 5

A. CML or Ph-positive ALL cells were treated with ponatinib or rigosertib, both, or imatinib for 72 h. Cell viability was determined as described in the Methods; *P < 0.05 compared with ponatinib or imatinib treatment. B. Lysates from primary cells treated with or without rigosertib for 24 h were immunoblotted using the indicated antibodies. C. Cells were treated with ponatinib, rigosertib, or both for 24 h. Whole extracts were examined via immunoblotting with anti-phospho ABL, phospho-Crk-L, cleaved caspase 3, cleaved-PARP and β-actin antibodies. CML, chronic myeloid leukemia; ALL, acute lymphoblastic leukemia; PARP, poly (ADP-ribose) polymerase.